Editas
Editas Medicine Lays off 65 Percent of Workforce; Drops Sickle Cell, TDT Candidate Reni-Cel
Editas, which was unable to identify a development or licensing partner for reni-cel, is focusing its resources on its in vivo pipeline.
Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on investigational candidates.
Editas Seeking Partner or Licensing Deal for Lead Sickle Cell, TDT Gene-Editing Treatment Candidate
The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
Editas Medicine Raises $57M by Selling Future Payments From CRISPR Licensing Deal With Vertex Pharma
Editas will receive $57 million in upfront cash from DRI Healthcare Trust in exchange for certain future licensing fees and payments it is owed under an earlier deal with Vertex.
Eleven of 14 patients with Leber congenital amaurosis, type 10, improved on at least one clinical outcome being monitored in the Phase I/II study.